Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice
Formalin-inactivated respiratory syncytial virus (FI-RSV), a lysate of HEp-2 cells and proteins F, G and N, immunopurified from infected cell cultures, were compared for their ability to prevent infection and to enhance changes in lung cytology associated with RSV challenge. Mice were immunized at three weekly intervals with serial dilutions of the preparations and challenged by the nasal route 1 week after the last injection; their lungs were analysed 4 days later. The concentration of the immunogens was adjusted to test at least a range of 2 to 500 ng of proteins per injection. The dose of FI-RSV used for immunization influenced both the protection against infection and the potentiation of lung histopathology. There was a strong correlation between the lesion scores and the proportion of larger cells recovered in bronchoalveolar lavage fluid. We therefore used cytological changes as an index of lung alterations in further experiments. Glycoproteins F and G but not protein N were protective against challenge infection. Potentiation was observed in mice immunized with minute amounts (2 ng per injection) of F, G or N. HEp-2 cell lysate also caused potentiation but this required greater than 125 ng of proteins per injection.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1992 |
|---|---|
| Erschienen: |
1992 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Vaccine - 10(1992), 2 vom: 04., Seite 113-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vaux-Peretz, F [VerfasserIn] |
|---|
| Themen: |
1HG84L3525 |
|---|
| Anmerkungen: |
Date Completed 30.03.1992 Date Revised 28.07.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM015209547 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM015209547 | ||
| 003 | DE-627 | ||
| 005 | 20231221062654.0 | ||
| 007 | tu | ||
| 008 | 231221s1992 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0051.xml |
| 035 | |a (DE-627)NLM015209547 | ||
| 035 | |a (NLM)1539464 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vaux-Peretz, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice |
| 264 | 1 | |c 1992 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.1992 | ||
| 500 | |a Date Revised 28.07.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Formalin-inactivated respiratory syncytial virus (FI-RSV), a lysate of HEp-2 cells and proteins F, G and N, immunopurified from infected cell cultures, were compared for their ability to prevent infection and to enhance changes in lung cytology associated with RSV challenge. Mice were immunized at three weekly intervals with serial dilutions of the preparations and challenged by the nasal route 1 week after the last injection; their lungs were analysed 4 days later. The concentration of the immunogens was adjusted to test at least a range of 2 to 500 ng of proteins per injection. The dose of FI-RSV used for immunization influenced both the protection against infection and the potentiation of lung histopathology. There was a strong correlation between the lesion scores and the proportion of larger cells recovered in bronchoalveolar lavage fluid. We therefore used cytological changes as an index of lung alterations in further experiments. Glycoproteins F and G but not protein N were protective against challenge infection. Potentiation was observed in mice immunized with minute amounts (2 ng per injection) of F, G or N. HEp-2 cell lysate also caused potentiation but this required greater than 125 ng of proteins per injection | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antigens, Viral |2 NLM | |
| 650 | 7 | |a HN Protein |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 650 | 7 | |a Viral Envelope Proteins |2 NLM | |
| 650 | 7 | |a Viral Proteins |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 650 | 7 | |a attachment protein G |2 NLM | |
| 650 | 7 | |a Formaldehyde |2 NLM | |
| 650 | 7 | |a 1HG84L3525 |2 NLM | |
| 700 | 1 | |a Chapsal, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Meignier, B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 10(1992), 2 vom: 04., Seite 113-8 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:1992 |g number:2 |g day:04 |g pages:113-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 1992 |e 2 |b 04 |h 113-8 | ||